Gradientech and Cellectric enter innovative collaboration to speed up sepsis diagnostics
The diagnostics company Gradientech today announces the collaboration with Vienna-based Cellectric on a new proof-of-concept study of a direct-from-blood application to speed up sepsis diagnostic workflows.
Cellectric is developing a direct-from-blood application for sepsis samples, selectively destroying human cells in the patient sample with the aim to bypass the need for culturing of the bacteria. The technology focuses on isolating target bacteria within minutes to accelerate the sepsis diagnosis workflow, with the goal of enabling faster, more effective sepsis patient management.
“We are excited to join forces with Gradientech, whose ultra-rapid AST platform is already setting new standards in clinical microbiology,” says Terje Wimberger, Managing Director at Cellectric. “Together, we will explore how the technology of Cellectric can resolve sample complexity and improve overall workflow efficiency, ultimately contributing to faster, more accurate treatment decisions for sepsis patients worldwide.”
“Cellectric’s cutting-edge approach to rapidly isolating bacteria directly from whole blood is true innovation. When combined with the ultra-rapid QuickMIC system, we can together not just improve workflows—we can redefine what’s possible in sepsis diagnostics and set a new benchmark for innovation in the clinical diagnostics market,” says Sara Thorslund, co-founder and CEO at Gradientech.
Contact
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
Terje Wimberger, PhD, Managing Director
Tel: +43 676 43 41 666